92 related articles for article (PubMed ID: 34666605)
1. Economic burden to commercial payers of young adults with schizophrenia in Colorado.
Pesa J; Patel C; Rotter D; Papademetriou E; Potluri R; Benson C
J Med Econ; 2021; 24(1):1194-1203. PubMed ID: 34666605
[TBL] [Abstract][Full Text] [Related]
2. Real-world analysis of insurance churn among young adults with schizophrenia using the Colorado All-Payer Claims Database.
Pesa J; Rotter D; Papademetriou E; Potluri R; Patel C; Benson C
J Manag Care Spec Pharm; 2022 Jan; 28(1):26-38. PubMed ID: 34949116
[No Abstract] [Full Text] [Related]
3. Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia.
Fu AZ; Pesa JA; Lakey S; Benson C
BMC Psychiatry; 2022 Apr; 22(1):250. PubMed ID: 35395757
[TBL] [Abstract][Full Text] [Related]
4. Healthcare resource utilization and cost among individuals with late-onset versus adult-onset Huntington's disease: a claims‑based retrospective cohort study.
To TM; Ta JT; Patel AM; Arndorfer S; Abbass IM; Gandhy R
J Med Econ; 2023; 26(1):862-870. PubMed ID: 37350423
[TBL] [Abstract][Full Text] [Related]
5. Healthcare resource utilization and costs in individuals with Huntington's disease by disease stage in a US population.
Exuzides A; To TM; Abbass IM; Ta JT; Patel AM; Surinach A; Fuller RLM; Luo J
J Med Econ; 2022; 25(1):722-729. PubMed ID: 35608039
[TBL] [Abstract][Full Text] [Related]
6. Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States.
Jain SS; Li SS; Xie J; Sutton MB; Fine JT; Edelberg JM; Gao W; Spertus JA; Cohen DJ
J Med Econ; 2021; 24(1):1115-1123. PubMed ID: 34493144
[TBL] [Abstract][Full Text] [Related]
7. Real-World Evaluation of Direct and Indirect Economic Burden Among Endometriosis Patients in the United States.
Soliman AM; Surrey E; Bonafede M; Nelson JK; Castelli-Haley J
Adv Ther; 2018 Mar; 35(3):408-423. PubMed ID: 29450864
[TBL] [Abstract][Full Text] [Related]
8. Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants.
Chowdhury R; Franchino-Elder J; Wang L; Yuce H; Wang C; Hartaigh BO
J Med Econ; 2019 Dec; 22(12):1338-1350. PubMed ID: 31549883
[No Abstract] [Full Text] [Related]
9. Health Care Resource Use, Costs, and Diagnosis Patterns in Patients With Schizophrenia and Bipolar Disorder: Real-world Evidence From US Claims Databases.
Broder MS; Greene M; Chang E; Hartry A; Touya M; Munday J; Yan T
Clin Ther; 2018 Oct; 40(10):1670-1682. PubMed ID: 30193748
[TBL] [Abstract][Full Text] [Related]
10. Burden of illness in patients with possible Lennox-Gastaut syndrome: A retrospective claims-based study.
Reaven NL; Funk SE; Montouris GD; Saurer TB; Story TJ
Epilepsy Behav; 2018 Nov; 88():66-73. PubMed ID: 30241056
[TBL] [Abstract][Full Text] [Related]
11. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.
Droege M; Sproule D; Arjunji R; Gauthier-Loiselle M; Cloutier M; Dabbous O
J Med Econ; 2020 Jan; 23(1):70-79. PubMed ID: 31322019
[No Abstract] [Full Text] [Related]
12. Economic burden of treatment-resistant depression in privately insured US patients with co-occurring anxiety disorder and/or substance use disorder.
Zhdanava M; Kuvadia H; Joshi K; Daly E; Pilon D; Rossi C; Morrison L; Lefebvre P; Nelson C
Curr Med Res Opin; 2021 Jan; 37(1):123-133. PubMed ID: 33124940
[TBL] [Abstract][Full Text] [Related]
13. Are Medicaid Coverage Gaps Associated with Higher Health Care Resource Utilization and Costs in Patients with Schizophrenia?
Pilon D; El Khoury AC; Manceur AM; Zhdanava M; Benson C; Lefebvre P; Doshi JA
Popul Health Manag; 2020 Jun; 23(3):234-242. PubMed ID: 31592717
[TBL] [Abstract][Full Text] [Related]
14. Resource utilization and cost in a commercially insured population with schizophrenia.
Fitch K; Iwasaki K; Villa KF
Am Health Drug Benefits; 2014 Jan; 7(1):18-26. PubMed ID: 24991388
[TBL] [Abstract][Full Text] [Related]
15. Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis.
Stein EM; Bonifacio G; Latrémouille-Viau D; Shi S; Guérin A; Wu EQ; Sadek I; Cao X
J Med Econ; 2021; 24(1):234-243. PubMed ID: 33472483
[TBL] [Abstract][Full Text] [Related]
16. Economic burden of sarcoidosis in a commercially-insured population in the United States.
Rice JB; White A; Lopez A; Conway A; Wagh A; Nelson WW; Philbin M; Wan GJ
J Med Econ; 2017 Oct; 20(10):1048-1055. PubMed ID: 28678623
[TBL] [Abstract][Full Text] [Related]
17. Excess healthcare resource utilization and healthcare costs among privately and publicly insured patients with major depressive disorder and acute suicidal ideation or behavior in the United States.
Zhdanava M; Voelker J; Pilon D; Joshi K; Morrison L; Sheehan JJ; Vermette-Laforme M; Lefebvre P; Citrome L
J Affect Disord; 2022 Aug; 311():303-310. PubMed ID: 35597466
[TBL] [Abstract][Full Text] [Related]
18. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
19. Direct and Indirect Cost Burden and Change of Employment Status in Treatment-Resistant Depression: A Matched-Cohort Study Using a US Commercial Claims Database.
Amos TB; Tandon N; Lefebvre P; Pilon D; Kamstra RL; Pivneva I; Greenberg PE
J Clin Psychiatry; 2018; 79(2):. PubMed ID: 29474009
[TBL] [Abstract][Full Text] [Related]
20. Prevalence, incidence and economic burden of schizophrenia among Medicaid beneficiaries.
Pilon D; Patel C; Lafeuille MH; Zhdanava M; Lin D; Côté-Sergent A; Rossi C; Joshi K; Lefebvre P
Curr Med Res Opin; 2021 Oct; 37(10):1811-1819. PubMed ID: 34281472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
